Revenue

For the fourth year, inDrive is the world's #2 ride-hailing app. Its secret? A unique pricing model and a bold expansion into an all-in-one super app.

A $1.2 billion deal sees Brookfield take Peakstone private, capping a successful pivot to industrial real estate and highlighting the IOS market's boom.

The acquisition of Steward Creek Solar, one of the nation's largest, signals a major push to meet surging power demand and grid challenges in the US.

As the surety market faces new challenges, Rosenberg & Parker brings in Michael Bogansky to fortify its financial strategy for a new era of expansion.

The firm's major investment in VA and NC blends value-add buys with new builds, navigating complex local markets to chase regional growth.

A new campaign from ZOLL LifeVest and the AHA targets the deadly disparity in women's cardiac care, blending advocacy with life-saving wearable technology.

AI identity firm Trust Stamp unveils a bold 2026 plan, targeting acquisitions, African markets, and the stablecoin economy to fuel its global expansion.

Intuit's QuickBooks will exclusively integrate Affirm's BNPL, letting SMBs get paid upfront while customers pay over time to fix cash flow issues.

Go inside Power Digital's strategy, where employee empowerment, proprietary AI, and strategic acquisitions have earned it a top spot on Ad Age's list.

Following strong Texas sales, cbdMD brings its Herbal Oasis THC seltzer to Louisiana, betting on a market eager for functional alcohol alternatives.

A major private equity investment in The Forge Companies signals a shift toward integrated financial planning for a complex and fragmented settlement market.

From automated bookings to data-driven operations, a new tech tide is rising, promising greater efficiency for operators and better experiences for boaters.

Burberry and Coty launch Hero Elixir, a potent new fragrance exploring duality and competing in the high-stakes, ultra-premium men's scent market.

With its largest fund yet, the firm is doubling down on breakthrough biotech and medtech, signaling strong investor faith in deep science innovation.

With a massive new investment, CyberFOX plans to accelerate AI development and acquisitions, aiming to reshape the security landscape for underserved MSPs.

A new liquid biopsy more accurately predicts cancer recurrence than standard methods, offering new hope and clarity for patients after surgery.

vTv Therapeutics shores up its finances with a deal worth up to $135M, sharpening its focus on a breakthrough Type 1 diabetes drug, cadisegliatin.

A $2.5B revitalization project enters a new phase, as Vornado and Newmark aim to transform a transit hub into NYC's premier 24/7 destination.

The firm's strategic relocation to an amenity-rich retail hub signals deep confidence in the Sunbelt and a new vision for the modern corporate office.

With a major Phase 3 trial now in Europe, Crystalys Therapeutics aims to fill a critical gap in gout care with a drug already proven in Asian markets.